

This listing of claims will replace all prior versions, and listings, of claims in the application:


Listing of Claims:

1. (Canceled).
2. (Canceled).
3. (Canceled).
4. (Canceled).
5. (Canceled).
6. (Canceled).
7. (Canceled).
8. (Currently Amended) ~~Compounds according to Claim 1 selected from the group A compound of the formula~~
N-1-[(4-chlorophenyl)]-N-2-{{4-(2-{dimethylaminomethyl}phenyl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
N-1-[(4-ethynylphenyl)]-N-2-{{4-(2-{dimethylaminomethyl}phenyl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
N-1-[(4-chlorophenyl)]-N-2-{{2-fluoro-4-(2-{dimethylaminomethyl}phenyl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
N-1-[(4-ethynylphenyl)]-N-2-{{2-fluoro-4-(2-{dimethylaminomethyl}phenyl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

N-1-[(4-chlorophenyl)]-N-2-[(4-(2-dimethylaminomethylimidazol-1-yl)-phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
N-1-[(4-ethynylphenyl)]-N-2-[(4-(2-dimethylaminomethyl-imidazol-1-yl)-phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
N-1-[(4-chlorophenyl)]-N-2-[(2-fluoro-4-(2-dimethylaminomethyl-imidazol-1-yl)phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
N-1-[(4-ethynylphenyl)]-N-2-[(2-fluoro-4-(2-dimethylamino-methylimidazol-1-yl)phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
N-1-[(4-chlorophenyl)]-N-2-[(4-(N,N-dimethylamidino)phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
N-1-[(4-ethynylphenyl)]-N-2-[(4-(N,N-dimethylamidino)phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
N-1-[(4-chlorophenyl)]-N-2-[(2-fluoro-4-(N,N-dimethylamidino)phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
N-1-[(4-ethynylphenyl)]-N-2-[(2-fluoro-4-(N,N-dimethylamidino)phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
N-1-[(4-chlorophenyl)]-N-2-[(4-(1-methyl-4,5-dihydro-1H-imidazol-2-yl)-phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
N-1-[(4-chlorophenyl)]-N-2-[(2-fluoro-4-(1-methyl-4,5-dihydro-1H-imidazol-2-yl)phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
N-1-[(4-ethynylphenyl)]-N-2-[(4-(1-methyl-4,5-dihydro-1H-imidazol-2-yl)-phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
N-1-[(4-ethynylphenyl)]-N-2-[(2-fluoro-4-(1-methyl-4,5-dihydro-1H-imidazol-2-yl)phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

and/or pharmaceutically usable derivatives, solvates, salts and/or stereoisomers thereof, including mixtures thereof in all ratios.

9. (Currently Amended) Process for the preparation of compounds of the formula I



in which

R denotes Hal, -C≡C-H, -C≡C-A or OA,


R¹ denotes H, =O, Hal, A, OH, OA, A-COO-, Ph-(CH₂)_n-COO-, cycloalkyl-(CH₂)_n-COO-, A-CONH-, A-CONA-, Ph-CONA-, N₃, NH₂, NO₂, CN, COOH, COOA, CONH₂, CONHA, CON(A)₂, O-allyl, O-propargyl, O-benzyl, =N-OH, =N-OA or =CF₂,

R² denotes H or A,

Ph denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by A, OA, OH or Hal,

R³ denotes H, Hal or A,

R⁴ denotes -C₆H₄-(CH₂)_n-NR⁵R^{5'}, -C(=NR⁵)NR⁵R^{5'},



R⁵, R⁵' each, independently of one another, denote H or A,


A denotes unbranched, branched or cyclic alkyl having 1-12 C atoms, in which, in addition, 1-7 H atoms may be replaced by F and/or chlorine,

Hal denotes F, Cl, Br or I,

n denotes 0, 1, 2 or 3,

according to Claim I and/or pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, characterised in that comprising reacting


a) a compound of the formula II



in which R has the meaning indicated in Claim 1,

is reacted with a chloroformate derivative to give an intermediate carbamate derivative,

which is subsequently reacted reacting said intermediate with a compound of the formula III




in which

R¹, R², R³ and R⁴ have the meaning indicated in Claim 1,

or

b) reacting a compound of the formula III

is reacted with a compound of the formula IV




in which

~~R has the meaning indicated in Claim 1,~~


or

c) reacting a compound of the formula V



~~in which R^3 and R^4 have the meaning indicated in Claim 1,~~

~~is reacted with a compound of the formula VI~~



in which

L denotes Cl, Br, I or a free or reactively functionally modified OH group
and

~~R, R^1 and R^2 have the meanings indicated in Claim 1,~~

and/or converting

~~a base or acid of the formula I is converted into one of its salts.~~

10. (Currently Amended) ~~Compounds of the formula I according to Claim 1 as~~

inhibitorsA method of coagulation factor Xa, comprising administering to a host in need thereof a compound of claim 8 or a pharmaceutically useable derivative, salt or stereoisomer thereof.

11. (Canceled).
12. (Currently Amended) MedicamentsA pharmaceutical composition comprising at least one compound of the formula I according to Claim 1 and/or pharmaceutically usable derivatives, ~~solvates~~, salts and stereoisomers thereof, including mixtures thereof in all ratios, and ~~optionally pharmaceutically acceptable~~ excipients and/or adjuvants.
13. (Canceled).
14. (Previously Presented) Use of compounds according to Claim 1 and/or physiologically acceptable salts and solvates thereof for the preparation of a medicamentA method for the treatment of thromboses, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty, claudicatio intermittens, migraine, tinnitus, tumours, tumour diseases and/or tumour metastases, comprising administering to a host in need thereof an effective amount of a compound of claim 8 and/or pharmaceutically useable derivatives, salts or stereoisomers thereof.
15. (Previously Presented) Set (kit) consisting of separate packs of
 - (a) an effective amount of a compound of the formula I according to Claim 1 and/or pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios,
and
 - (b) an effective amount of a further medicament active ingredient.

16. (Canceled).